Safe Use of Systemic Interferons for Multiple Sclerosis Treatment
- Авторлар: Snegireva I.I.1, Darmostukova M.A.1, Kazakov A.S.1, Lepakhin V.K.1
-
Мекемелер:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- Шығарылым: Том 52, № 10 (2019)
- Беттер: 863-864
- Бөлім: Drugs
- URL: https://journal-vniispk.ru/0091-150X/article/view/245514
- DOI: https://doi.org/10.1007/s11094-019-1916-8
- ID: 245514
Дәйексөз келтіру
Аннотация
The safety of interferons was assessed by analyzing 499 spontaneous reports in the Russian database from 2015 to 2017. The results led to the conclusion that the safety profile of systemic interferon preparations that are widely used in medical practice to treat multiple sclerosis is defined by data in spontaneous reports for the development of adverse reactions to them or the ineffectiveness of using them.
Негізгі сөздер
Авторлар туралы
I. Snegireva
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Хат алмасуға жауапты Автор.
Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051
M. Darmostukova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051
A. Kazakov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051
V. Lepakhin
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: SnegirevaII@expmed.ru
Ресей, 8/2 Petrovskii Blvd, Moscow, 127051
Қосымша файлдар
